Jorge Cortes, MD - Third-Line Therapies in Chronic Myeloid Leukemia: Evolving to Overcome the Limitations of Early-Generation Tyrosine Kinase Inhibitors

episode

CME in Minutes: Education in Oncology & Hematology not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Pretty Little Episode #110 26 min · 25 Sep 2026 · Handsome

Ireland collapse in Kosovo as Israel game looms 13 min · 25 Sep 2026 · Today with David McCullagh

Living Breakthrough-Minded | Joel Osteen 30 min · 25 Sep 2026 · Joel Osteen Podcast

4AM ET 09/25/2026 Newscast 3 min · 25 Sep 2026 · Fox News Hourly Update

The Week: Trump vs the Press, Meta’s AI Win, and the Turning Political Tide 22 min · 25 Sep 2026 · The Prof G Pod with Scott Galloway

Gabrielle Lyon Part 2 1h 1m · 25 Sep 2026 · unPAUSED with Dr. Mary Claire Haver

Report any issue

Source

Recorded13 Nov 2023

Publisherc.answersincme.com ↗

Handlerec:766062

Show notes

Please visit answersincme.com/RPM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses available third-line therapies for patients with chronic myeloid leukemia. Upon completion of this activity, participants should be better able to: Describe treatment challenges with available therapeutic options as chronic myeloid leukemia (CML) progresses; Review the available clinical data for third-line agents in CML; and Differentiate between third-line CML treatments based on patient, drug, and disease factors.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in